Trial Profile

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezisterim (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms ADdRESs-LC
Sponsors BioVie

Most Recent Events

15 May 2025 According to the BioVie Media Release, The Phase 2 ADDRESS-LC study is fully funded by a grant from the U.S. Department of Defense (DOD)
15 May 2025 According to the BioVie Media Release, company announced that the first patient has been enrollment in the Phase 2 ADDRESS-LC clinical trial. The Company anticipates topline data to be available in the first half of 2026.
22 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com